The Clinical Times
The Front Page of Medicine

Latest medical news · page 183

The latest headlines across every section, pulled from official and open-access sources.

FDA Drugs · Jun 15, 2026

What You Should Know about Eye Drops

Ophthalmic drug products, such as eye drops, pose a heightened risk of harm to users because drugs applied to the eyes bypass some of the body’s natural defenses. Any drug used in the eyes must be sterile to reduce the risk of infection. Eye drops are available by prescription or sold as OTCs.

FDA Drugs · Jun 15, 2026

Human Drug Compounding

Compounded drugs can serve an important medical need for certain patients, they also present a risk to patients.

ACC (Cardiology) · Jun 15, 2026

ACC Comments on 2027 IPPS Proposed Rule

The ACC submitted comments to the Centers for Medicare and Medicaid Services (CMS) regarding the fiscal year 2027 Inpatient Prospective Payment System (IPPS) proposed rule.

FDA Drugs · Jun 15, 2026

Section 804 Importation Program Policies and Authorizations

FDA has issued policies and taken actions to implement section 804 of the Federal Food, Drug and Cosmetic Act, which allows states and Indian tribes to import certain prescription drugs from Canada. Learn more.

MedCity News · Jun 15, 2026

Don’t Leave Healthcare’s Greatest Asset Behind on the Road to Interoperability

In the push toward a more seamless, digitally enabled future, it’s important we understand exactly how this rush to interoperability may actually harm patients, instead of helping, and what we can do to make sure they keep pace. The post Don’t Leave Healthcare’s Greatest Asset Behind on the Road to Interoperability appeared first on MedCity News .

FDA Drugs · Jun 15, 2026

Human Drug Imports

Human drug import information including PLAIR, safe importation action plan, and personal importation policy.

FDA Drugs · Jun 15, 2026

Shipment Admissibility

FDA reviews drug shipments at land and seaports, courier hubs and international mail facilities to determine whether they are admissible into the U.S. FDA uses a multi-layered, risk-based approach to identify violative imported drugs, combining data screening and physical examinations.

FDA Drugs · Jun 15, 2026

Importing Investigational New Drugs

An investigational new drug (IND) imported for use in clinical studies must be covered by an IND application, unless exempt per 21 CFR 312.2. The company should submit the IND to FDA before importing the drug into the U.S.

FDA Drugs · Jun 15, 2026

Importing Active Pharmaceutical Ingredients

Active pharmaceutical ingredients (APIs) imported or offered for import into the U.S. must comply with all the applicable requirements and regulations under the Food Drug & Cosmetic (FD&C) Act and Title 21 of the Code of Federal Regulations (21 CFR).

FDA Drugs · Jun 15, 2026

Importing Drugs with a Pre-Launch Activities Importation Request (PLAIR)

FDA reviews requests and may grant permission in certain circumstances for a manufacturer to import a drug in anticipation of the drug receiving FDA approval. When approved, these pre-launch activities importation requests, or PLAIRs, allow drug sponsors to import unapproved finished drugs.

FDA Drugs · Jun 15, 2026

Importing Over-The-Counter Drugs

Over-the-counter (OTC) or non-prescription drugs imported into the U.S. must comply with all the applicable requirements under the Federal, Food and Cosmetic Act (FD&C Act) and the pertinent regulations in Title 21 of the Code of Federal Regulations (21 CFR).

FDA Drugs · Jun 15, 2026

General Requirements for Importing Human Drugs

FDA verifies that drugs imported or offered for import into the U.S. meet federal law requirements at the time of import to protect patients and consumers.

FDA Drugs · Jun 15, 2026

Importing Prescription Drugs

Prescription drugs imported into the U.S. must comply with all the applicable requirements under the Federal, Food and Cosmetic Act (FD&C Act) and the pertinent regulations in Title 21 of the Code of Federal Regulations (21 CFR).

← NewerOlder →

Back to the live front page